About Pricing FAQs Blog

Loading clinical trials...

Clareo Health Find Clinical Trials →

© 2026 Clareo Health. All rights reserved.

Osteoporosis Clinical Trials | 353 Studies Recruiting | Clareo Health

Clinical TrialsOsteoporosis

Osteoporosis Clinical Trials

Browse 353 clinical trials for osteoporosis. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 341-353 of 353 trials

COMPLETEDPHASE4

Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo

NCT00532246

The purpose of this study is to measure carotid artery IMT at a single visit in a subset of women previously enrolled in the CORE (H3S-MC-GGJY) trial

Osteoporosis, Post-Menopausal

Eli Lilly and Company147 participantsStarted Mar 2003

La Jolla, California, United States • Menlo Park, California, United States • Oakland, California, United States +2 more locations

COMPLETEDPHASE3

Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

NCT00532207

To see if using teriparatide for 12 months will increase Bone Mineral Density at the lumbar spine in postmenopausal women with osteoporosis

Osteoporosis, Post-Menopausal

Eli Lilly and Company50 participantsStarted Nov 2003

Related Searches

bone densitytrials

Data from ClinicalTrials.govTerms

Body Composition, Bone Mineral Density, Insulin Sensitivity and Echocardiographic Measurements in Klinefelter Syndrome

NCT00523835

Klinefelter syndrome (KS) is the most common sex-chromosome disorder with a prevalence of one in 660 men and is a frequent cause of hypogonadism and infertility. It is caused by the presence of extra X-chromosomes, the most common karyotype being 47,XXY. The phenotype is variable, but the most constant finding is small hyalinized testes, hypergonadotrophic hypogonadism, infertility, eunuchoid body proportion, increased height and learning disabilities. Klinefelter syndrome has been associated with increased prevalence of diabetes, osteoporosis and cardiovascular diseases but the pathogenesis is unknown. Accordingly the aim of the study was to investigate measures of body composition, insulin sensitivity, bone mineral density, echocardiography, as well as biochemical markers of endocrine, metabolic and bone function in KS and an age-matched control group.

Klinefelter SyndromeDiabetesOsteoporosis+2 more

University of Aarhus140 participantsStarted Apr 2002

Aarhus, Denmark

COMPLETEDPHASE4

2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis

NCT00191425

The primary purpose of the study is to compare 3 different osteoporosis therapies following one year of teriparatide.In the first year,all eligible patients received open-label teriparatide 20 micrograms/day.After 1 year, patients are randomly assigned to one of 3 possible follow-up treatment regimens for the second 12 months: continuation of teriparatide, switch to raloxifene, or no pharmacological treatment(other than the calcium and vitamin D supplements that everyone receives). Patients are stratified into 3 subsets: (a) patients who have never received any anti-osteoporosis treatment before; (b) patients who received prior antiresorptive treatment successfully; (c) patients who failed to respond adequately to prior antiresorptive drugs (such as bisphosphonates or raloxifene) in the past. These latter patients are not randomized at month 12 but will continue treatment with teriparatide 20 micrograms/day throughout the second year.

Osteoporosis, Postmenopausal

Eli Lilly and Company810 participantsStarted Aug 2002

Bad Pyrmont, Germany

COMPLETEDPHASE1

Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women

NCT00395395

This is a phase I study to analyze the effect of water and food intake on the bioavailability and pharmacodynamic of oral salmon calcitonin (SMC021) and salmon calcitonin nasal spray in post-menopausal women.

Postmenopausal Osteoporosis

Novartis56 participantsStarted Oct 2006

Multiple Cities, Denmark

The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.

NCT00346190

To determine whether administration of Alendronate early is more effective than late in the prevention of osteoporosis following a hip fracture

McGill University Health Centre/Research Institute of the McGill University Health Centre10 participantsStarted Jan 2003

Montreal, Quebec, Canada

COMPLETEDPHASE3

Compliance and Acceptance of Teriparatide Injection in Severely Osteoporotic Patients

NCT00191802

The purposes of this study are to evaluate the acceptance of the subcutaneous drug teriparatide over 6 months of therapy in patients with severe osteoporosis in Canada, and to evaluate how often such patients are actually able to use the injection; to obtain additional safety data (side effect data) that will supplement the existing database of adverse events that have been reported to-date in clinical trials by patients treated with teriparatide; to document the prior use of other osteoporosis therapies in this patient population, and ongoing use of other osteoporosis therapies during the study; and to describe the baseline demographics and disease state of these severely osteoporotic patients.The purposes of the study extension are to continue to assess the acceptance of the subcutaneous drug teriparatide over up to 18 months of therapy in patients with severe osteoporosis in Canada, and to continue to assess how often such patients are actually able to use the injection; to obtain additional safety data (side effects) that will supplement the existing database of adverse events that have been reported to date in clinical trials by patients treated with teriparatide.

Eli Lilly and Company120 participantsStarted Sep 2003

Calgary, Alberta, Canada • Edmonton, Alberta, Canada • Vancouver, British Columbia, Canada +10 more locations

COMPLETEDPHASE3

Upper GI Handling of Branded vs. Generic Alendronate

NCT00400530

To compare upper GI handling of fosamax and generic, because the main AE profile of alendronate is before systemic absorption in the esophagus; differences could be relevant to the side effect profile.

Merck Sharp & Dohme LLC25 participantsStarted Dec 2005

COMPLETEDPHASE3

Effect of Calcium and Vitamin D on Bone Loss From the Hip

NCT00357643

The primary aim of this study is to determine the effects of supplementation with both calcium and vitamin D on changes in bone density of the hip in men and women age 65 and older.

Tufts University450 participantsStarted Oct 1992

Boston, Massachusetts, United States

COMPLETEDPHASE4

The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients

NCT00114556

Following liver transplantation, rapid bone loss occurs, particularly within the first 6 months post-transplant. This may be associated with fractures, most notable vertebral. The ability to assess osteoporosis therapies in this system may provide useful information for osteoporosis management in general. Hypotheses: 1. That treatment with the bisphosphonate, zoledronate, at the time of liver transplantation and at 1 month post-transplantation will prevent the early transplant-related bone loss (measured by bone densitometry and biochemical bone markers at 3 months) seen in patients who are not treated with a bisphosphonate 2. That continuing treatment with zoledronate at 3 monthly intervals for a total duration of 12 months will result in further improvements in bone density beyond that seen at 3 months 3. That calcium and vitamin D (vit D) supplementation of liver transplant patients does not prevent marked bone loss following transplantation.

OsteoporosisLiver TransplantationFractures

Royal Prince Alfred Hospital, Sydney, Australia100 participantsStarted Feb 2000

Sydney, New South Wales, Australia

Safety and Efficacy Study of Bugusan (BGS)to Treat Osteoporosis.

NCT00202956

The objective is to evaluate the effects on biomarkers and safety of BGS in postmenopausal patients with osteoporosis.

Taichung Veterans General HospitalStarted Jun 2004

Taichung, Taiwan

Osteoporosis in Children and Adults Following Liver Transplantation

NCT00008788

This pilot project aims to 1) estimate the prevalence of osteoporosis in adults having undergone liver transplantation in childhood, and 2) identify risk factors for osteoporosis in this group. We aim to study 40 individuals.

OsteoporosisLiver Transplantation

National Center for Research Resources (NCRR)40 participants

Minneapolis, Minnesota, United States

Randomized Study of Growth Hormone on Bone Mineral Density in Patients With Adult Onset Growth Hormone Deficiency

NCT00006394

OBJECTIVES: I. Compare whether the bone tissue in the spine and hip improves in patients with adult onset growth hormone deficiency treated with growth hormone (GH) vs placebo. II. Determine whether the blood samples of these patients show evidence of beneficial bone effects after treatment with GH. III. Compare the quality of life of these patients treated with these 2 regimens. IV. Determine the side effects of GH in these patients.

OsteoporosisGrowth Hormone Deficiency

National Center for Research Resources (NCRR)72 participantsStarted Apr 1997

Boston, Massachusetts, United States • Rochester, Minnesota, United States • St Louis, Missouri, United States +4 more locations

PreviousPage 18 of 18